市场趋势
| 短期 | 中期 | ||
| 行业 | Diagnostics & Research (US) | 混合的 | 看涨 |
| Diagnostics & Research (全球的) | 混合的 | 看涨 | |
| 股票 | Personalis, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
-0.9
| 分析师共识 | NA |
| 内部交易活动 | -3.0 |
| 价格波动 | -3.5 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.88 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| 部门 | Healthcare |
| 行业 | Diagnostics & Research |
| 投资方式 | Small Value |
| 内部持股比例 | 31.49% |
| 机构持股比例 | 46.11% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Merck & Co., Inc. | 30 Jun 2026 | 14,044,943 |
| Ark Investment Management Llc | 30 Jun 2026 | 8,271,339 |
| Lightspeed Management Company, L.L.C. | 30 Jun 2026 | 6,101,850 |
| Deep Track Capital, Lp | 30 Jun 2026 | 4,000,000 |
| Aberdeen Group Plc | 30 Jun 2026 | 3,747,290 |
| Casdin Capital, Llc | 30 Jun 2026 | 2,550,000 |
| Aigh Capital Management Llc | 30 Jun 2026 | 1,715,000 |
| Blue Water Life Science Advisors, Lp | 30 Jun 2026 | 1,676,300 |
该时间范围内无数据。
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| CHEN RICHARD | - | 16.40 | -3,998 | -65,567 |
| HALL CHRISTOPHER M | - | 16.40 | -7,459 | -122,328 |
| MOORE STEPHEN MICHAEL | - | 16.40 | -2,068 | -33,915 |
| TACHIBANA AARON | - | 16.40 | -2,931 | -48,068 |
| 累积净数量 | -16,456 | |||
| 累积净值 ($) | -269,878 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 16.40 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| TACHIBANA AARON | 职员 | 18 Sep 2026 | 卖 (-) | 2,931 | 16.40 | 48,068 |
| HALL CHRISTOPHER M | 职员 | 18 Sep 2026 | 卖 (-) | 7,459 | 16.40 | 122,328 |
| MOORE STEPHEN MICHAEL | 职员 | 18 Sep 2026 | 卖 (-) | 2,068 | 16.40 | 33,915 |
| CHEN RICHARD | 职员 | 18 Sep 2026 | 卖 (-) | 3,998 | 16.40 | 65,567 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合